Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Fluorospectrometer for Cancer Research

By Drug Discovery Trends Editor | July 7, 2010





 

Thermo Fisher Scientific Inc. introduces an application note demonstrating how the Thermo Scientific NanoDrop 3300 enables cancer researchers to study DNA methylation events and polyamine induced DNA G-quadruplex formations by microvolume fluorometry. The fluorospectrometer allows researchers to perform fluorescence measurements simply, quickly and cost-effectively, making the instrument a valuable tool for cancer research and biomedical research applications.


This new application note reviews methods in the current literature where the fluorospectrometer enables scientists to investigate complex DNA structures within the field of cancer research. The application note provides an insight into the benefits of using fluorescence spectroscopy for proof of concept experimentation of DNA methylation detection assays, as well as DNA G-quadruplex analysis.


Fluorescence spectroscopy methodologies are also aiding the targeting of and delivery to cancer cells in vivo to correct defects, inhibit growth and induce apoptosis. In addition, the technique provides excellent sensitivity and specificity for researchers working in this field. The patented “cuvette-less” sample retention system employed by the fluorospectrometer enables fluorescent measurements using as little as one microlitre sample volume. The fluorospectrometer is also capable of analyzing multiple emission profiles from a single sample. In addition, the easy-to-use instrument has a small footprint, taking up minimal space in the laboratory.


Thermo Fisher Scientific Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50